Similar articles

• Introduction: targeting different pathways to prevent tumor cell development.

  Kantarjian HM. Kantarjian HM. Semin Oncol. 2009 Apr;36(2 Suppl 1):S1-5. doi: 10.1053/j.seminoncol.2009.02.003. Semin Oncol. 2009. PMID: 19393830 No abstract available.
• Novel therapeutic targets.

  Farley J, Birrer MJ. Farley J, et al. Cancer Treat Res. 2009;149:63-84. doi: 10.1007/978-0-387-98094-2_3. Cancer Treat Res. 2009. PMID: 19763431 Review. No abstract available.
• HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

  Nielsen DL, Andersson M, Kamby C. Nielsen DL, et al. Cancer Treat Rev. 2009 Apr;35(2):121-36. doi: 10.1016/j.ctrv.2008.09.003. Epub 2008 Nov 12. Cancer Treat Rev. 2009. PMID: 19008049 Review.
• [Pharmacogenetics and tailored drug therapy].

  Nielsen FC, Borregaard N. Nielsen FC, et al. Ugeskr Laeger. 2009 Mar 2;171(10):790-4. Ugeskr Laeger. 2009. PMID: 19265602 Danish.
• Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.

  LaCasce AS, Freedman AS. LaCasce AS, et al. Semin Hematol. 2008 Apr;45(2):85-9. doi: 10.1053/j.seminhematol.2008.02.004. Semin Hematol. 2008. PMID: 18381102 Review.